Integrated motivational interviewing and cognitive behavioural therapyfor people with psychosis and comorbid substance misuse: Randomised controlled trial

BMJ (Online)

Volumn 341, Issue 7784, 2010, Pages 1204-

  Barrowclough, Christine ^a   Haddock, Gillian ^a   Wykes, Til ^b   Beardmore, Ruth ^a   Conrod, Patricia ^b   Craig, Tom ^b   Davies, Linda ^a   Dunn, Graham ^a   Eisner, Emily ^a   Lewis, Shôn ^a   Moring, Jan ^c   Steel, Craig ^d   Tarrier, Nicholas ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c GREATER MANCHESTER MENTAL HEALTH NHS FOUNDATION TRUST   (United Kingdom)

^d UNIVERSITY OF READING   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOLISM; ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITIVE THERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DEPENDENCE; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MOTIVATION; PATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; SUBSTANCE ABUSE; SYMPTOM; TREATMENT OUTCOME; ADDICTION; ADULT; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; HOSPITALIZATION; METHODOLOGY; MULTICENTER STUDY; PATIENT COMPLIANCE; PSYCHOSIS; RECURRENT DISEASE; STATISTICS;

ADULT; COGNITIVE THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HOSPITALIZATION; HUMANS; INTERVIEWS AS TOPIC; MALE; MOTIVATION; PATIENT COMPLIANCE; PSYCHOTIC DISORDERS; RECURRENCE; SUBSTANCE-RELATED DISORDERS; TREATMENT OUTCOME;

EID: 78649855189     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c6325     Document Type: Article

References (46)

1. Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA 1990;264:2511-8.
2. Graham HL, Copello A, Birchwood MJ, Maslin J, McGovern D, Orford J, et al. The combined psychosis and substance use (COMPASS) programme: an integrated, shared care approach. In: Graham HL, Copello A, Birchwood MJ, Mueser KT, eds. Substance misuse in psychosis: approaches to treatment and service delivery. John Wiley & Sons, 2003:106-20.
3. Weaver T, Rutter D, Madden P, Ward J, Stimson G, Renton A. Results of a screening survey for co-morbid substance misuse amongst patients in treatment for psychotic disorders: prevalence and service needs in an inner London borough. Soc Psychiatry Psychiatr Epidemiol 2001;36:399-406.
4. Dixon L, Haas G, Weiden PJ, Sweeney J, Frances AJ. Drug abuse in schizophrenic patients: clinical correlates and reasons for use. Am J Psychiatry 1991;148:224-30.
5. Maslin J. Substance misuse in psychosis: contextual issues. In: Graham HL, Copello A, Birchwood MJ, Mueser KT, eds. Substance misuse in psychosis: approaches to treatment and service delivery. John Wiley & Sons, 2003:3-23.
6. Cleary M, Hunt GE, Matheson SL, Siegfried N, Walter G. Psychosocial interventions for people with both severe mental illness and substance misuse. Cochrane Database Syst Rev 2008;1:CD001088.
7. Department of Health. Mental health policy implementation guide: dual diagnosis good practice guide. DH, 2002.
8. Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AL, Henry RJ, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract 2005;11:315-406.
9. Baker A, Lewin T, Reichler H, Clancy R, Carr V, Garrett R, et al. Evaluation of a motivational interview for substance use within psychiatric in-patient services. Addiction 2002;97:1329-37.
10. Barrowclough C, Haddock G, Tarrier N, Lewis SW, Moring J, O'Brien R, et al. Randomised controlled trial of cognitive behavioural therapy plus motivational intervention for schizophrenia and substance use. Am J Psychiatry 2001;158:1706-13.
11. Miller WR, Rollnick S. Motivational interviewing: preparing people for change. 2nd ed. Guilford Press, 2002.
12. Martins RK, McNeil DW. Review of motivational interviewing in promoting health behaviours. Clin Psychol Rev 2010;29;283-93.
13. Hettema J, Steele J, Miller WR. Motivational interviewing. Annu Rev Clin Psychol 2005;1;91-111.
14. Stewart SH, Conrod PJ. Introduction to the special issue on state-of-the-art cognitive-behavioral interventions for substance use disorders. J Cogn Psychother 2005;19:195-8.
15. Dutra L, Stathopoulu G, Basden SL, Leyro TM, Powers MB, Otto MW. A meta-analytic review of psychosocial interventions for substance use disorders. Am J Psychiatry 2008;165:179-87.
16. Denis C, Lavie E, Fatseas M, Auriacombe M. Psychotherapeutic interventions for cannabis abuse and/or dependence in outpatient settings. Cochrane Database Syst Rev 2006;3:CD005336.
17. Wykes T, Steel C, Everitt B, Tarrier N. Cognitive behaviour therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008;34:523-37.
18. National Institute for Health and Clinical Excellence. Schizophrenia: core interventions in the treatment and management of schizophrenia in adults in primary and secondary care (update). NICE, 2009.
19. Haddock G, Barrowclough C, Tarrier N, Moring J, O'Brien R, Schofield N, et al. Cognitive-behavioural therapy and motivational intervention for schizophrenia and substance misuse: 18 month outcomes of a randomised controlled trial. Br J Psychiatry 2003;183:418-26.
20. Boutron I, Moher D, Altman DG, Schulz KF, Ravaud P. Extending the CONSORT statement to randomized trials of nonpharmacologic treatment: explanation and elaboration. Ann Intern Med 2008;148:295-309. (Pubitemid 351665487)
21. Schulz K, Altman DG, Moher D, for the CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332.
22. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010;340:c869.
23. First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis 1 disorders - clinician version (SCID-CV). American Psychiatric Press, 1997.
24. Barrowclough C, Haddock G, Beardmore R, Conrod P, Craig T, Davies L, et al. Evaluating integrated MI and CBT for people with psychosis and substancemisuse: recruitment, retention and sample characteristics of the MIDAS trial. Addict Behav 2009;34:859-66.
25. Haddock G, Beardmore R, Earnshaw P, Fitzsimmons M, Nothard S, Butler R, et al. Assessing fidelity for integrated motivational interviewing and CBT therapy for psychosis and substance use: the MI-CTS fidelity scale. J Ment Health (submitted 2010).
26. Saunders JB, Aasland OG, Babor TF, de la Fuente JR, Grant M. Development of the Alcohol Use Identification Test (AUDIT): WHO collaborative project on early detection of persons with harmful alcohol consumption-II. Addiction 1993;88:791-804. (Pubitemid 23194530)
27. Babor T, Higgins-Biddle JC, Saunders JB, Monteiro MG. The alcohol use disorders identification test: guidelines for use in primary care. 2nd ed. World Health Organization, 2001.
28. Skinner HA. The drug abuse screening test. Addict Behav 1982;7:363-71.
29. Alexander D, Leung P. The Marijuana Screening Inventory (MSI-X): concurrent, convergent and discriminant validity with multiple measures. Am J Drug Alcohol Abuse 2006;32:351-78.
30. Hogan TP, Awad AG, Eastwood R. A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13:177-83.
31. Cicchetti D. Guidelines, criteria and rules of thumb for evaluating normed and standardized assessment instruments in psychology. Psychol Assess 1994;6:284-90.
32. Rollnick S, Heather N, Gold R, Hall W. Development of a short 'readiness to change' questionnaire for use in brief opportunistic interventions among excessive drinkers. Br J Addict 1992;87:743-54.
33. Blanchard KA, Morgenstern J, Morgan TJ, Labouvie EW, Bux DA. Assessing consequences of substance use: psychometric properties of the Inventory of Drug Use Consequences. Psychol Addict Behav 2003;17:328-31.
34. Sobell LC, Sobell MB. Timeline follow back: a technique for assessing self-reported alcohol consumption. In: Litten RZ, Allen JP, eds. Measuring alcohol consumption: psychosocial and biochemical methods. Humana Press Inc, 1992:41-72.
35. Carey KB. Reliability and validity of the time-line follow-back interview among psychiatric outpatients: a preliminary report. Psychol Addict Behav 1997;11:26-33.
36. Carey KB, Carey MP, Maisto SA, Henson JM. Temporal stability of the timeline follow-back interview for alcohol and drug use with psychiatric outpatients. J Stud Alcohol 2004;65:774-81.
37. Stasiewicz P, Vincent PC, Bradizza CM, Connors GJ, Maisto SA, Mercer ND. Factors affecting agreement between severelymentally ill alcohol abusers' and collaterals' reports of alcohol and other substance use. Psychol Addict Behav 2008;22:78-87.
38. Drake RE, Mueser KT, McHugo GJ. Clinician rating scales: alcohol use scale (AUS), drug use scale (DUS), and substance abuse treatment scale (SATS). In: Sederer LI, Dickey B, eds. Outcomes assessment in clinical practice. Williams & Wilkins, 1996:113-6.
39. Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13:261-76.
40. American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-IV). 4th ed. American Psychiatric Association, 1994.
41. White H. Maximum likelihood estimation of misspecified models. Econometrica 1982;50:1-25.
42. Miller WR, Wilbourne PL. Mesa Grande: a methodological analysis of clinical trials of treatments for alcohol use disorders. Addiction 2002;97:265-77.
43. Kaner EF, Dickinson HO, Beyer FR, Campbell F, Schlesinger C, Heather N, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev 2007;2:CD004148.
44. Edwards J, Elkins K, Hinton M, Harrigan S, Donovan K, Athanasopoulos O, et al. Randomised controlled trial of a cannabis-focused intervention for young people with first-episode psychosis. Acta Psychiatr Scand 2006;114:109-17. (Pubitemid 44034269)
45. Baker A, Bucci S, Lewin TJ, Kay-Lambkin F, Constable PM, Carr VJ. Cognitive-behavioural therapy for substance use disorders in people with psychotic disorders: randomised controlled trial. Br J Psychiatry 2006;188:439-48.
46. Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new behavioural treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry 2006;63:426-32.